Dance Biopharm said today that it has partnered with DarioHealth (NSDQ:DRIO) to integrate Dance’s smart inhaler into DarioHealth’s digital therapeutics program.

Durham, N.C.-based Dance Biopharm’s smart inhaler includes vibrating mesh designed to create a soft mist that improves medication coverage in the lung. In clinical trials, the device delivered insulin in mist form with a faster drug onset and comparable duration to subcutaneous delivery of rapid insulin for patients with Type 2 diabetes.

Israel-based DarioHealth’s digital platform includes the MyDario application, a data-driven blood glucose monitoring system with an optional connected blood pressure monitoring system.

Get the full story at our sister site, Drug Delivery Business News.